- Home
- NVCT vs SLGL Comparison
NVCT vs SLGL Comparison
Compare NVCT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCT | SLGL |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 247.1M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NVCT | SLGL |
|---|---|---|
| Price | $8.95 | $77.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $110.00 |
| AVG Volume (30 Days) | 47.8K | ★ 51.4K |
| Earning Date | 05-06-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $0.62 |
| 52 Week High | $11.52 | $97.97 |
Technical Indicators
Market Signals| Indicator | NVCT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 50.60 |
| Support Level | $8.03 | $71.01 |
| Resistance Level | $9.20 | $84.75 |
| Average True Range (ATR) | 0.43 | 5.40 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 80.49 | 47.96 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.